Home
RNA Therapeutics
9 February - 10 February 2022

If you have registered for this conference, please click this link to login and join. Your login details should have been sent to you by portal@smi-online.co.uk

RNA Therapeutics

SAE Media Group’s 13th Annual Conference
RNA Therapeutics
9-10 February, 2022 | Virtual Conference
-------------------------------------------------------------------------
SAE Media Group is proud to announce the 13th Annual RNA Therapeutics Conference taking place on 9 - 10 February 2022

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.


The RNA therapeutics industry has grown at an exponential rate in recent years, with an increased spotlight following the industry’s leading role in developing vaccines against COVID-19 in response to the global pandemic. This year’s conference will reflect on how the industry has adapted and played a pivotal role in global health over the past year and will discuss the takeaways for future mRNA therapeutic development. Furthermore, the 2022 agenda will explore innovations in novel and targeted delivery, RNAi innovations and antisense oligonucleotide therapeutics. Global experts from big pharma and leading biotechs will explore the emerging therapeutic applications of RNA with case studies on the treatment of cardiovascular disease, neurological diseases and oncology.

Join us in February 2022, as SAE Media Group’s 13th annual RNA Therapeutics Conference brings together industry experts from leading RNA therapeutics companies to gain an expert and holistic view on the latest developments of the industry.
 

FEATURED SPEAKERS

Alfica Sehgal

Alfica Sehgal

VP Head of Discovery, CAMP4 Therapeutics
Arun Kumar

Arun Kumar

Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
Brid Ryan

Brid Ryan

VP Immuno-Oncology Research, MiNA Therapeutics
Cristina R. Reschke

Cristina R. Reschke

Lecturer, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland
David Lowe

David Lowe

Vice President, Evox Therapeutics Ltd
Dong Ki Lee

Dong Ki Lee

CEO, OilX Pharmaceuticals
Eric Lim

Eric Lim

Associate Director, Bioinformatics, Stoke Therapeutics, Inc
Gareth Morris

Gareth Morris

ERUK Emerging Leader Research Fellow, University College London
Gayatri Arun

Gayatri Arun

Vice President of Biology, Envisagenics Inc
Heinrich Haas

Heinrich Haas

Vice President RNA Formulation and Drug Delivery, BioNTech
Jimmy Weterings

Jimmy Weterings

Principal Scientist, AstraZeneca
Kirsty Wydenbach

Kirsty Wydenbach

Deputy Unit Manager/Senior Medical Assessor, MHRA
Martin Akerman

Martin Akerman

CTO & Co-Founder, Envisagenics
Michael T. Migawa

Michael T. Migawa

Executive Director, Medicinal Chemistry and Oligonucleotide Chemistry, Ionis Pharmaceuticals Inc.
Michel Janicot

Michel Janicot

Chief Development Officer, InteRNA Technologies BV
Nagy Habib

Nagy Habib

Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
Rea Lardelli

Rea Lardelli

Senior Scientist, RNA Biology, Locanabio
Samir Ounzain

Samir Ounzain

CEO, HAYA Therapeutics
Sudhir Agrawal

Sudhir Agrawal

Founder and President, ARNAY Sciences
Thomas Thum

Thomas Thum

Founder and Chief Scientific Officer, Cardior Pharmaceuticals
Volker Germaschewski

Volker Germaschewski

Senior Vice President of Research & Development, eTheRNA Immunotherapies NV

Alfica Sehgal

VP Head of Discovery, CAMP4 Therapeutics
Alfica Sehgal

Alfica is VP at CAMP4, heading the discovery, preclinical and translational research. Before CAMP4, she was at Alnylam Pharmaceuticals, where she held multiple roles. Alfica was the program leader for Alpha-1 antitrypsin deficiency related liver disease, driving the program from bench to Phase 1, as well as the program research lead for the fitusiran program for the treatment of haemophilia and rare bleeding disorders. She was also a member of the platform team and next wave team responsible for generating and triaging new pipeline programs.
Alfica received her post-doctoral training at Johns Hopkins University and Yale University, studying lipid uptake, cholesterol and oxygen homeostasis in parasites, mammalian cells and mice. She received her doctoral degree from the Tata Institute of Fundamental Research (India) in naturally acquired immunity against malarial parasites. She has published more than 30 articles and book chapters in peer-reviewed journals and has authored 17 patents and PCT applications.
 

Arun Kumar

Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
Arun Kumar

Dr. Arun Kumar is a Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging/re-emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he worked on the several vaccine development programs based on the messenger RNA technology. He has focused his career on the next-generation platform technologies for vaccine development and translational sciences. At CEPI, he currently leading global preclinical vaccine development programs, and co-leading the CEPI Centralized Global Laboratory Network. He also manages various international collaborative activities.
Dr. Kumar holds a Ph.D. in Viral Immunology and Infectious diseases from the University of Helsinki, Finland.

 

Brid Ryan

VP Immuno-Oncology Research, MiNA Therapeutics
Brid Ryan

Bríd joined MiNA in 2021 and is VP for immuno-oncology research. Previously, she spent 14 years at the National Cancer Institute in the USA where she led a team focussed on lung cancer research. She has extensive experience in the design and conduct of studies to advance the understanding and clinical management of cancer across the fields of basic science, immunology, and molecular biology. She has published widely in oncology, precision medicine, and biomarkers. Bríd has a PhD in Cancer Biology and Master of Public Health from University College Dublin.

Cristina R. Reschke

Lecturer, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland
Cristina R. Reschke

Cristina Reschke is Lecturer in the School of Pharmacy and Biomolecular Sciences at the RCSI University of Medicine and Health Sciences and a Funded Investigator of the FutureNeuro Research Centre. She trained as a Pharmacist with a M.Sc. (2010) and Ph.D. (2013) in Pharmacology with research focusing on the effects of neuroinflammation in epilepsy (UFSM, Brazil). Cristina then joined Prof. David Henshall’s group in Ireland to advance discoveries on the role of microRNAs in experimental and human epilepsy. Her work has been internationally awarded, including prestigious young neuroscientists Awards endowed by the International League Against Epilepsy (ILAE) and the American Epilepsy Society (AES). In 2020, Cristina was the recipient of the inaugural CURE Epilepsy Cameron Boyce Foundation Taking Flight Award to establish her own laboratory and investigate the impact of the circadian rhythm dysregulation in epilepsy. Cristina actively serves the Young Epilepsy Section (YES) of the ILAE supporting the training of a new generation of epilepsy experts poised to discover and deliver state-of-the-art care to people with epilepsy well into the future.


 

David Lowe

Vice President, Evox Therapeutics Ltd
David Lowe

David’s extensive experience at Astra Zeneca includes having accountability for the isolation and optimisation of antibodies, proteins, and peptides for therapeutic development. He and his team delivered lead molecules for the Respiratory, Inflammatory, and Autoimmunity antibody projects. David was the Global Head of In Vivo Expressed Biologics at AZ focusing on exploring and advancing new technologies such as AAV, DNA, mRNA and exosome delivery of biologics. David spent nearly 10 years at Cambridge Antibody Technology, prior to it being acquired by Astra Zeneca, where he led antibody engineering to develop novel antibody-based drugs. David has over 40 scientific publications, and is an inventor on numerous patents. David earned his Ph.D. from the University of Cambridge.d Process Development at AZ and holds an MSc in Biochemistry and Biotechnology.

Dong Ki Lee

CEO, OilX Pharmaceuticals
Dong Ki Lee

Professor of Chemistry, Sungkyunkwan University, Korea
Founder and CEO, OliX Pharmaceuticals, Korea

Prof. Dong-ki Lee received B. S. in Chemistry from Korea Advanced Institute of Science and Technology (KAIST) in 1993, and Ph. D. in Biochemistry from Cornell University in 1999. After post-doctoral training in Pohang University of Science and Technology (POSTECH), Toolgen Inc., and KAIST, he joined POSTECH as an assistant professor in 2004. In 2008, He moved to Sungkyunkwan University and is a full professor of Chemistry since 2012. In 2008, Prof. Lee was selected as the principal investigator of the Global Research Laboratory program, funded by Korean government, to develop novel RNAi medicine. He is currently serving as the Asian editor of “Nucleic Acid Therapeutics” and a editorial board member of "Molecular Therapy: Nucleic Acids". His work on novel siRNA structures, nucleic acid aptamers, and eukaryotic gene regulation has been published as over 80 papers including prestigious journals such as Nature, Cell, PNAS, and Molecular Therapy. In 2010, he founded OliX Pharmaceuticals, a publicly traded RNAi therapeutics company, and serves as Chief Executive Officer.
 

Eric Lim

Associate Director, Bioinformatics, Stoke Therapeutics, Inc
Eric Lim

With a background in Computer Science and Mathematics, Eric received his Ph.D. in Molecular Biology, Cell Biology, and Biochemistry from Fairbrother Lab at Brown University. His work focused on using a combination of computational biology and high throughput genomics techniques to identify functional splicing elements in the genome. Eric has a decade of post-postdoctoral experience in the biotech industry and is currently the Head of Bioinformatics at Stoke Therapeutics, where he leads a team of computational scientists in leveraging oligonucleotides as a modality to treat the underlying cause of genetic diseases. Before Stoke, he was a co-investigator of a team at the Children's Hospital of Philadelphia to support research into potential treatments for an aggressive form of pediatric leukemia. His prior research also involved the development of preclinical cancer genomics in identifying preferential anti-tumor activities of a small molecule in blood cancers and solid tumors. Eric has over 24 publications and patents in the field of RNA splicing and his work has led to numerous awards, including the 40 Under 40 in Cancer.

Gareth Morris

ERUK Emerging Leader Research Fellow, University College London
Gareth Morris

Gareth completed his PhD at the University of Birmingham in 2014, studying high frequency brain oscillations in epilepsy. He then worked as a postdoc at University College London’s Institute of Neurology, as part of the EU ‘EpimiRNA’ consortium. Since then he has made numerous key contributions to the field of microRNA and epilepsy, winning several national and international research prizes. In 2021 Gareth completed a Marie Sklodowska-Curie Actions Individual Fellowship at the Royal College of Surgeons in Ireland, and has recently started his own research group at University College London with funding from Epilepsy Research UK.

Gayatri Arun

Vice President of Biology, Envisagenics Inc
Gayatri Arun

Dr. Gayatri Arun serves as the Vice President of Biology at Envisagenics. Dr. Arun has received her Ph.D. in Molecular Biology and Genetics from JNCASR, Bangalore, India and had her postdoctoral training at Cold Spring Harbor Laboratory in New York. Dr. Arun has more than 15 years of research experience in RNA biology understanding RNA regulation in various diseases and antisense-based therapeutic development for long noncoding RNAs. She currently leads the research and product development for targets and therapeutics for alternative splicing derived targets in oncology, neurodegenerative, and other indications.

Heinrich Haas

Vice President RNA Formulation and Drug Delivery, BioNTech
Heinrich Haas

Heinrich has more than 20 years of experience in academic research and industrial pharmaceutical development. His focus is on development for advanced drug delivery systems. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems. He was responsible for projects in different biopharmaceutical companies for research and development of diagnostic and therapeutic carrier systems. Joining BioNTech in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules.

Jimmy Weterings

Principal Scientist, AstraZeneca
Jimmy Weterings

jimmy

Kirsty Wydenbach

Deputy Unit Manager/Senior Medical Assessor, MHRA
Kirsty Wydenbach

Dr Kirsty Wydenbach is a Senior Medical Assessor and the Deputy Unit Manager in the Clinical Trials Unit, having joined the MHRA in 2009. She has been involved in the UK regulation of clinical trials across all therapy areas and all phases of development, including ATMPs and many first-in-man studies. She has also been involved in European discussions aiming to establish an EU harmonised approach to clinical trials, particularly for Developmental Safety Update Reports (DSURs) and Reference Safety Information (RSI). She was also an EMA expert for the update of the First-in-Human guideline. Other recent work has included collaboration with external industry groups and regulators regarding adaptive and novel trial designs: she is leading on this aspect for the MHRA in order to implement that aspect of the Life Sciences Industrial Strategy, and was a contributor to the EU CTFG “Recommendation Paper on the Initiation and Conduct of Complex Clinical Trials”. More recently Kirsty has overseen the clinical trial work for COVID-19 and provided regulatory expertise on vaccines both within MHRA but also as part of the government Vaccine Taskforce.

 

Martin Akerman

CTO & Co-Founder, Envisagenics
Martin Akerman

Martin Akerman is the Co-founder and CTO of Envisagenics. He is the inventor of the SpliceCore® platform, Envisagenics’ flagship AI technology for the discovery of splicing-based therapeutic targets. Martin trained as a post doctorate fellow with Dr. Adrian Krainer from Cold Spring Harbor Laboratory. He received his PhD in Bioinformatics from Technion, Israel Institute of Technology. As a first-time entrepreneur, Martin represented Envisagenics in winning the J&J AI for Drug Discovery QuickFire challenge in 2017 and Microsoft’s Innovate.AI challenge in 2018. His goal is to combine cutting-edge computation with RNA domain expertise to develop innovative drugs for cancer and genetic diseases.

Michael T. Migawa

Executive Director, Medicinal Chemistry and Oligonucleotide Chemistry, Ionis Pharmaceuticals Inc.
Michael T. Migawa

Michael T. Migawa has over 20 years of experience in oligonucleotide research and is currently the Executive Director of Oligonucleotide Chemistry at Ionis Pharmaceuticals. Prior to that, he worked in the Medicinal Chemistry Department at Ionis focusing on novel chemical entities to improve ASO therapeutics. Dr. Migawa earned his Ph.D. in Chemistry from the University of Michigan at Ann Arbor working with Leroy B. Townsend on novel nucleoside analogs.

Michel Janicot

Chief Development Officer, InteRNA Technologies BV
Michel Janicot

Michel holds a Ph.D. degree in Biochemistry (Paris VII. France) and was Postdoctoral Fellow in the Dept. of Biological Chemistry (M. Daniel Lane) at The Johns Hopkins University (Baltimore, MD. USA). He has over 25-years hands-on experience in Oncology preclinical and early clinical pharmaceutical drug development in increasing leadership and managerial roles at Rhone-Poulenc Rorer (Sanofi) and subsequently, at Janssen (Johnson & Johnson). Since 2012, Michel is the founder and Managing Director of JMi ONConsulting, a Brussels-based consulting firm specialized in providing services and guidances for research and development programs in Oncology, Inflammation, Immunology, Vaccines, COPD, MS, Diabetes, Fibrosis and Ophthalmology.

Nagy Habib

Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics
Nagy Habib

Nagy Habib is a leading translational researcher on liver cancer and its treatment. He pioneered the first clinical trial in the use of adenovirus and plasmid for the treatment of liver cancer, as well as the use of plasmid gene therapy in hydrodynamic gene delivery. He is the first person in the West to publish a clinical trial on the use of adult bone marrow derived stem cells for the treatment of patients with liver insufficiency.

He has published on the evolution of molecular biology of tumours from oncogene, tumour suppressor gene, epigenetic modification, gene therapy, stem cell therapy, RNA (Ribonucleic acid) and saRNA (small activating RNA) and RNA aptamers.

He is the inventor of, and was co-author of the first publication about the use for radiofrequency in devices used in liver surgery (Habib™ 4X), as well as interventional endoscopy (Habib™ EndoHPB – HPB: Hepatopancreatobiliary) and interventional radiology (Habib™ Percutaneous HPB, Habib™ VesCoag, Habib™ VesOpen).

Nagy is currently Lead Clinician and Head of the Department of HPB Surgery at Imperial College London. In June 2007 he was also appointed Pro Rector for Commercial Affairs at the university. He holds a gold award from the Advisory Committee for Clinical Excellence, which is given in recognition of exceptional contributions from NHS consultants, and he was named as one of Britain’s top surgeons in December 2011 by the Saturday Times Magazine. In December 2012, he was awarded the TAKREEM AWARD for Science and Technology for scientific work in liver cancer and the technological development of the Habib 4X surgical device. In 2015, Nagy was awarded a Foreign Membership of the prestigious French Académie Nationale de Chirurgie.
 

Rea Lardelli

Senior Scientist, RNA Biology, Locanabio
Rea Lardelli

Rea Lardelli, PhD, joined Locanabio in February 2020 and is Senior Scientist in RNA biology. She leads the splicing modulation team and serves as the functional leader for Locanabio’s ocular program. Before coming to Locanabio, Rea was an NRSA and IRACDA postdoctoral fellow at University of California, San Diego and the Ludwig Institute for Cancer Research in Melbourne, Australia where her studies focused on molecular mechanisms of post-transcriptional regulation. Rea received her doctoral degree in Biochemistry from The University of Texas, where she studied RNA-protein complexes, and her BS from Cal Poly, San Luis Obispo.

Rok Sekirnik

Head of Process Development, mRNA pDNA, BIA Separations
Rok Sekirnik

Rok Sekirnik graduated with a degree in chemistry from the University of Oxford, where he also completed his PhD. His team at BIA Separations, now a Sartorius company, is focused on developing high-yielding, cost-effective purification approaches for pDNA and mRNA production.

Samir Ounzain

CEO, HAYA Therapeutics
Samir Ounzain

Samir Ounzain is a molecular biologist with over 15 years of experience exploring the dark matter of the genome and its roles in development and disease. Prior to founding HAYA Therapeutics, Samir was a Project Leader and Research Fellow at the Lausanne University Hospital (CHUV), where his research efforts directly led to the discovery of hundreds of novel heart-enriched lncRNAs, most notably the lncRNAs CARMEN, Meteor and Wisper.

Steve Pascolo

Founder and CEO, Miescher Pharma GmbH
Steve Pascolo

Trained as an immunologist at the Pasteur Institute (Paris, France), Dr. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of mRNA and performing the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2017, Dr. Pascolo implemented in Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.
 

Sudhir Agrawal

Founder and President, ARNAY Sciences
Sudhir Agrawal

Sudhir Agrawal, D. Phil, FRSC is founder of ARNAY Sciences LLC. He is also serving as visiting professor in the department of medicine at University of Massachusetts Medical School, and a member of the business advisory board of Harvard Medical School’s Initiative for RNA Medicine. He is currently serving as a member of the scientific advisory boards of several biotechnology companies. He is also a founder of Idera Pharmaceuticals and has had held various leadership roles within the company, including Chairman, CEO, President of Research, and Chief Scientific Officer until 2017. Over the last three decades, his research has been focused on the discovery and development of RNA therapeutics. He has published over 300 research papers and is listed as a co-inventor of more than 400 patents worldwide. He has edited four books on oligonucleotides and antisense technology, including a recent book on ‘Advances in Nucleic Acid Therapeutics’ published in February 2019 by The Royal Society of Chemistry.

Tamar Grossman

Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson
Tamar Grossman

Dr. Tamar R. Grossman is the Global Head of RNA and Targeted Therapeutics at Janssen Pharmaceutical Companies of Johnson and Johnson. Tamar is responsible for the delivery of RNA based development candidates across all therapeutic areas. Previously, she was a Senior Director and Head of Rare Diseases at Arcturus Therapeutics where she developed RNA therapeutics across different RNA technologies. Prior to Arcturus, Tamar was the Director of Translational Medicine at Ionis Pharmaceuticals where she led various antisense oligonucleotide research programs to clinical development. She received her PhD in Biochemistry from Tel-Aviv University and complete postdoctoral research training at the UCSD.

Thomas Thum

Founder and Chief Scientific Officer, Cardior Pharmaceuticals
Thomas Thum

Thomas Thum studied medicine in Hannover, with state examination in 2001 and board examination for internal medicine/cardiology in 2009/2010. He received his PhD at the Imperial College, London (2008). He is a full professor and director of the Institute of Molecular and Translational Therapeutic Strategies at the Hannover Medical School (MHH), Visiting Professor at the Imperial College, director of MHH’s Center for Translational Regenerative Medicine and director of the Fraunhofer Institute for Toxicology and Experimental Medicine. He (co-) authored > 400 publications and >40 patents and is a distinguished reviewer, board member, and founder.

 

Volker Germaschewski

Senior Vice President of Research & Development, eTheRNA Immunotherapies NV
Volker Germaschewski

Volker Germaschewski, PhD joins from Kymab Ltd. (Cambridge, UK) where, over 10 years, he was initially Senior Director Discovery and subsequently Vice President of Haematology. Prior to that he held several positions in Biopharm R&D at GlaxoSmithKline.

sponsors

Conference agenda

clock

8:30

Registration & Coffee

clock

9:00

Chairman's Opening Remarks

Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech

clock

9:10

Development of RNA Therapeutics

Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech

  • Where do we come from, where do we stand, what are we heading for?
  • Delivery as a key challenge
  • LNPs and other lipid and non-lipid based nanoparticles
  • Some thoughts on general concepts to optimize RNA formulations
  • Future directions and challenges
  • clock

    9:50

    Policies relating to medicines and medical devices

    Kirsty Wydenbach, Deputy Unit Manager/Senior Medical Assessor, MHRA

  • An insight into the MHRA's approach to mRNA vaccines over the past year
  • MHRA updates and guidance on RNA therapeutics
  • Regulatory advice on novel clinical trials
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    mRNA: Removing Bottlenecks in Process Development and Manufacturing

    STREAM A: Novel Drug Products and Large Volume Delivery STREAM B: Sustainability for Injectable Delivery Devices
    14.00 Chair’s Opening Remarks
    Claus Geiger, Global Medical Device Leader, Sanofi
    14.00 Co-Chair’s Opening Remarks
    Cedric Gysel, Healthcare Solutions Manager, Johnson and Johnson
    Els Ducheyne, Senior Manager, Materials Compliance, Johnson and Johnson
    14.10 Developing Wearable Injectors for Large Volume and Highly Viscous Drugs
  • An insight into the current landscape and examples large volume wearable injectors on the market
  • Establishing the optimal volume range for an on-body device
  • Assessing the impact of viscosity on injection force and reducing intermolecular interactions
  • Case study on a wearable injector: delivering monoclonal antibodies
  • Using connectivity to assess performance of the wearable injector and medication administration Claus Geiger, Global Medical Device Leader, Sanofi
  • 14.10 Recycling Injectable Drug Devices: An Update
  • Discussion of creating end-of-life product solutions such as take-back pilots
  • Exploring the current challenges in re-purposing drug delivery devices
  • How can the challenges in launching take-back schemes be overcome?
  • Case Study on a real-world TakeBack Program and key takeaways
  • How can these programs be scaled-up? Niels Otterstrøm Jensen, Head of TakeBack Program, Novo Nordisk A/S Reusable devices
  • 14.40 Delivering large volume at home with a sustainable wearable injector platform
  • Challenges of large volume drugs for the Industry
  • Addressing chronic diseases with large volume drugs
  • Challenges for delivering large volume injections at home
  • Drivers for designing a sustainable platform to address all these challenges
  • Necessity of a patient-centric approach Cecile Gross, Category Manager for Parenteral Devices, Nemera
  • 14.40 Reserved Sponsor Session
    15.10 Platform Approaches to increase the Efficiency of your Injectable Portfolio
  • What delivery systems and devices are suitable for platforms and tailoring for a range of delivery volumes
  • Proven risk, clinical and usability testing for a successful platform
  • Challenges in using platforms for novel drug products and assessing when a platform is most beneficial for a product portfolio
  • How can platforms be utilised to maximise product success: A case study Eleanor Kimber, Principal Device Engineer, GSK
  • 15.10 Applying Circularity: Moving Towards Net Zero Drug Delivery Devices
  • Introduction to Alliance to Zero’s mission and work
  • Practical ways to calculate a product’s carbon footprint and assess the product life cycle
  • Strategic approaches to enable circular transformation
  • How stakeholders can collaborate to effectively develop more sustainable injection devices? Sebastian Gerner, President, Alliance to Zero
  • 15.40 Reserved sponsor session

    15.40 Reserved sponsor session

     

    Jimmy Weterings, Principal Scientist, AstraZeneca

    Michelle Lynn Hall

    Michelle Lynn Hall, Senior Director, Eli Lilly & Co - New Therapeutic Modalities

    Thomas Thum

    Thomas Thum, Director, Institute of Molecular and Translational Therapeutic Strategies , Hannover Medical School

    clock

    11:40

    Accelerated development of messenger RNA based COVID-19 candidate vaccines

    Arun Kumar, Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)

  • The development of mRNA-based vaccines is much faster compared to traditional approaches of vaccines development
  • There are more than 18 vaccines under clinical evaluation and at least 25 under preclinical development
  • mRNA platform technology promises to revolutionize future vaccines
  • CEPI’s current portfolio of mRNA-based vaccines and future directions
  • clock

    12:20

    Synthetic mRNA vaccines

    Steve Pascolo, Founder and CEO, Miescher Pharma GmbH

  • History of synthetic mRNA vaccines
  • Mode of action of natural and synthetic mRNA vaccines
  • Production and formulation of synthetic mRNA vaccines
  • Vaccines and therapies based on synthetic mRNA: now and in the future
  • clock

    13:00

    Networking Lunch

    clock

    14:00

    Exosomes as a multi-modular vehicle for RNA Therapeutics

    David Lowe, Vice President, Evox Therapeutics Ltd

  • Exosomes are naturally produced by all cells and play multiple roles in intercellular communication
  • Exosomes are an exciting, emerging potential therapy for serious diseases
  • At Evox we are engineering exosomes to deliver a wide variety of different RNA payloads in vivo
  • clock

    14:40

    Preclinical to clinical transition of INT-1B3 (LNP-formulated miR-193a-3p mimic): initial lessons learned

    Michel Janicot, Chief Development Officer, InteRNA Technologies BV

  • Moving from preclinical evaluation to first-in-human study
  • Initial PK/PD correlation from preclinical to clinical findings
  • Outlook: potential impact on clinical development acceleration
  • clock

    15:20

    Traversing protected tissue barriers for oligonucleotide delivery

    Michael T. Migawa, Executive Director, Medicinal Chemistry and Oligonucleotide Chemistry, Ionis Pharmaceuticals Inc.

  • Current challenges in delivery of oligonucleotide therapeutics
  • Insights into the use of Transferrin receptor ligands and other approaches to optimise delivery
  • Case Study: Enhancing potency of oligonucleotide therapeutics in muscle tissues
  • A future outlook for enhancing oligonucleotide delivery systems
  • clock

    16:00

    Afternoon Tea

    clock

    16:30

    A new era of programmable therapeutics to upregulate genes

    Alfica Sehgal, VP Head of Discovery, CAMP4 Therapeutics

  • RNAs role in genome organization and gene expression and insights into the current use of regulatory RNAs in industry
  • Targeting regRNA to increase gene expression and the use of RNA actuators to increase regRNA activity and restore levels of mRNA expression
  • Understanding the technology behind programmable therapeutics for RNA targets in conjunction with RNA actuator technology
  • Looking forward to pipelines in neurological and hepatocyte therapy
  • clock

    17:10

    Small Activating RNAs: From Concept to Phase 2 Clinical Trial

    Brid Ryan, VP Immuno-Oncology Research, MiNA Therapeutics

  • Small activating RNAs (saRNA) are double stranded 21 nucleotide RNA that either target promoters or enhance genes leading to mRNA upregulation
  • saRNAs can be delivered with liposomes into the systemic circulation or subcutaneously by conjugation with aptamers or GalNAC
  • MTL-CEBPA is an investigative drug that resulted from the conjugation of saRNA CEBPA with NOV 340 lipsomes that targets tumour associated macrophages in order to alter favourably the tumour microenvironment
  • MTL-CEBPA has been administered safely in over 100 patients with advanced cancer and improved clinical outcome in a sub-set of patients when co-administered with TKI or check point inhibitor
  • clock

    17:50

    Programmable mRNA-targeting gene therapy to correct genetic diseases

    Rea Lardelli, Senior Scientist, RNA Biology, Locanabio

  • An introduction to CORRECTX: Locanabio’s programmable RNA-binding protein platform 
  • Application of splicing modulation modality in ocular disease 
  • Emerging approaches for durable splice modulating therapeutics
  • clock

    18:30

    Chairman’s Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Coffee

    clock

    9:00

    Chairman's Opening Remarks

    Heinrich Haas, Vice President RNA Formulation and Drug Delivery, BioNTech

    clock

    9:10

    Therapeutic development using chemically modified asymmetric siRNAs

    Dong Ki Lee, CEO, OilX Pharmaceuticals

  • RNA interference (RNAi)-based gene silencing has become the 3rd therapeutic development platform with multiple FDA-approved RNAi drugs on market
  • OliX’s asymmetric siRNA (asiRNA) triggers efficient target gene silencing with reduced non-specific effects 
  • OliX Pharmaceuticlas has developed lipid-conjugated cp-asiRNA for local administration therapeutics, and GalNAc-asiRNA for liver targeting therapeutics
  • I will describe OliX Pharmaceuticals’ pre-clinical and clinical developments against various disease indications including (1) local administration therapeutics such as skin scar, androgenic alopecia, and age-related macular degeneration, (2) liver therapeutics such as hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and diabetes.
  • clock

    9:50

    Validation of therapeutic mode of action for heart failure program

    Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals

  • The landscape of microRNA for targeted therapy and miR-132’s key role in cardiovascular diseases
  • Investigating the molecular mechanisms of microRNAs in modulating cardiomyocyte contractility
  • Understanding the study findings and the approach of blocking miR-132 to halt the process of cardiac disease
  • What’s next? Moving on to phase 2 studies
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    Reimagining heart treatments via precision therapeutics

    Samir Ounzain, CEO, HAYA Therapeutics

  • Delving into HAYA’s innovative tissue- and cell-selective genomic medicines
  • How is the discovery engine using long coding RNAs to treat serious health conditions
  • Identifying novel targets and drug candidates with potential for greater efficacy and safety
  • Targeting Wisper and preclinical results showing the potential to reverse fibrotic processes and underlying heart failure
  • clock

    11:40

    Engineering the Future of mRNA Therapies

    Volker Germaschewski, Senior Vice President of Research & Development, eTheRNA Immunotherapies NV

  • Challenges and limitations of current mRNA technology
  • Applications for a developing technology and the tools to do it
  • The importance of process and supply
  • clock

    12:20

    Networking Lunch

    clock

    13:20

    Systematic identification of novel microRNA targets for epilepsy treatment

    Cristina R. Reschke, Lecturer, School of Pharmacy and Biomolecular Sciences, Royal College of Surgeons in Ireland

  • Temporal Lobe Epilepsy (TLE) and the therapeutic challenge – why do we need to address that?
  • MiRNAs as targets for epilepsy treatment - what do we know so far & what are we missing?
  • EpimiRNA project: Systematic identification of novel miRNA targets for seizure suppression in TLE
  • clock

    14:00

    MicroRNA-335 modulates voltage-gated sodium channels and may be a new therapeutic target in epilepsy

    Gareth Morris, ERUK Emerging Leader Research Fellow, University College London

  • MicroRNA-335 is dysregulated in drug-resistant epilepsies
  • MicroRNA-335 represses multiple voltage-gated sodium channels in the brain
  • Manipulation of microRNA-335 can alter brain excitability and may be beneficial in epilepsy
  • clock

    14:40

    RNA Therapeutics in Oncology: Advances and Challenges

    Gayatri Arun, Vice President of Biology, Envisagenics Inc

  • With the support of Envisagenics’ proprietary machine learning modules, high performance computing, and splicing analytics, Envisagenics identified a novel target and designed and validated RNA therapeutic compound in 8 months
  • Focusing on antisense oligonucleotides as a viable therapeutic modality in oncology and other applicable therapeutic areas
  • Overcoming limitations to computational outputs and executing necessary validation experiments for in-silico identified targets
  • clock

    15:20

    Afternoon Tea

    clock

    15:50

    The Evolution and Expansion of RNA-based Therapeutics

  • Defining applicable therapeutic areas for RNA-based therapeutics and the current promising and accepted disease areas
  • Investor outlook on RNA therapeutics and their appetite for RNA-based companies
  • Spectrum of RNA therapeutics (miRNA, ASO, mRNA, siRNA, etc.)
  • Roles of small molecules in RNA therapeutics
  • Modality comparison (small molecule vs. antisense; delivery vs. generalizable drugs) and pros and cons of RNA-based therapeutics
  • Martin Akerman, CTO & Co-Founder, Envisagenics

    Michel Janicot, Chief Development Officer, InteRNA Technologies BV

    Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals

    Nagy Habib, Head of HBP Surgery, Co-Founder, Imperial College London and MiNA Therapeutics

    Tamar Grossman, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson

    clock

    16:30

    Targeting the Noncoding Genome for the Development of RNA Therapies

    Samir Ounzain, CEO, HAYA Therapeutics

  • New concepts for the identification of tissue, cell-type, and disease specific regulatory ncRNA targets
  • RNA-targeting modalities and approaches to tame the genome's dark side
  • Translational potential of next-generation lncRNA targets
  • clock

    17:10

    The Successes and Failures of RNA-based Therapeutics and Future Outlook

  • Considerations of important characteristics and biology targeting RNA molecules directly.
  • Pipeline and process overview of target selection criteria and ensuring therapeutic viability and specificity.
  • Transforming antisense into a drug and taking sequence into consideration to understand potential off-target effects.
  • Drug delivery considerations, chemistry considerations, and IP strategy
  • Future outlook of RNA-based therapeutics (impact of COVID in the RNA field) and innovative companies in the last 10 years in this respective field
  • Martin Akerman, CTO & Co-Founder, Envisagenics

    Samir Ounzain, CEO, HAYA Therapeutics

    Sudhir Agrawal, Founder and President, ARNAY Sciences

    Eric Lim, Associate Director, Bioinformatics, Stoke Therapeutics, Inc

    Gayatri Arun, Vice President of Biology, Envisagenics Inc

    clock

    17:50

    Chairman’s Closing Remarks and Close of Day Two


    VP Head of Discovery
    CAMP4 Therapeutics
    Preclinical Vaccine Development Lead
    Coalition for Epidemic Preparedness Innovations (CEPI)
    VP Immuno-Oncology Research
    MiNA Therapeutics
    Lecturer, School of Pharmacy and Biomolecular Sciences
    Royal College of Surgeons in Ireland
    Vice President
    Evox Therapeutics Ltd
    CEO
    OilX Pharmaceuticals
    Associate Director, Bioinformatics
    Stoke Therapeutics, Inc
    ERUK Emerging Leader Research Fellow
    University College London
    Vice President of Biology
    Envisagenics Inc
    Vice President RNA Formulation and Drug Delivery
    BioNTech
    Principal Scientist
    AstraZeneca
    Deputy Unit Manager/Senior Medical Assessor
    MHRA
    CTO & Co-Founder
    Envisagenics
    Executive Director, Medicinal Chemistry and Oligonucleotide Chemistry
    Ionis Pharmaceuticals Inc.
    Chief Development Officer
    InteRNA Technologies BV
    Head of HBP Surgery, Co-Founder
    Imperial College London and MiNA Therapeutics
    Senior Scientist, RNA Biology
    Locanabio
    Head of Process Development, mRNA pDNA
    BIA Separations
    CEO
    HAYA Therapeutics
    Founder and CEO
    Miescher Pharma GmbH
    Founder and President
    ARNAY Sciences
    Global Head of RNA and Targeted Therapeutics
    Janssen Pharmaceutical Companies of Johnson & Johnson
    Founder and Chief Scientific Officer
    Cardior Pharmaceuticals
    Senior Vice President of Research & Development
    eTheRNA Immunotherapies NV

    Sponsors

    Exhibitors

    Supporters

    RNA Therapeutics Brochure 2022

    Download

    Preliminary Attendees

    Download

    Speaker Interview- Steve Pascolo, Miescher Pharma GmbH

    Download

    Speaker Interview - Martin Akerman, Evisagenics

    Download

    Speaker Interview - Nagy Habib, Imperial College London & MiNA Therapeutics

    Download

    Conference Chair Letter

    Download

    Chair & Speaker Biographies

    Download

    Past Attendees

    Download

    Past Speaker Presentations - Sarepta Therapeutics

    Download

    Past Speaker Presentations - ProQR

    Download

    Past Speaker Presentations - OilX

    Download

    Past Speaker Presentations - GSK

    Download

    Past Speaker Presentations - eTheRNA Immunotherapies

    Download

    Past Speaker Presentations - BioNTech

    Download

    Sponsors


    BIA Separations

    Sponsors
    http://www.biaseparations.com

    BIA Separations, now a Sartorius company, develops and manufactures market-leading CIM® monolithic chromatographic columns for purification and analysis of large biomolecules, such as viruses, plasmids and mRNA, which are applied in cell and gene therapies. BIA's technology for manufacturing-scale purification is already used in production of the first commercialized advanced therapeutics; BIA also has a keen presence with novel drug candidates in the clinical pipeline. Expecting continued strong double-digit sales growth over the next few years, BIA earned sales revenue approx. 25 million Euros in 2020, contributing to Sartorius Bioprocess Solutions, part of the Sartorius Group.



    eTheRNA

    Sponsors
    http://www.etherna.be

    eTheRNA is an mRNA technology platform company with integrated capabilities including mRNA construct design and optimization, coupled with specialized expertise in designing and manufacturing customized lipid nanoparticles (cLNP) formulations tailored for the prevention and treatment of various pathological states, providing end-to-end solutions for next generation mRNA therapeutics. The company believes that customized LNPs are critical enablers in advancing mRNA technologies to new levels of prophylactic and therapeutic utility.


    Exhibitors


    Thermofisher

    Exhibitors
    http://www.thermofisher.com

    ThermoFisher Scientific is a proven partner in the development and manufacture of nucleic acid therapeutics and mRNA vaccines. We offer a comprehensive product portfolio that spans the spectrum of nucleic acid therapeutic and vaccine development operations from early discovery to process development and commercial manufacturing.


    Media Partners


    Biocompare

    Supporters
    http://www.biocompare.com

    Biocompare.com is the leading resource for up-to-date product information, product reviews, and new technologies for life scientists. Biocompare combines an in-depth knowledge of life science products and new technologies with the power of the Internet to offer scientists the most dynamic, relevant, and innovative media-based marketplace for life science information.


    Genomeweb L L C

    Supporters
    http://www.genomeweb.com

    GenomeWeb LLC is an independent, privately-held online and print publisher based in New York. Since 1997, GenomeWeb has served the global community of scientists, technology professionals, and executives who use and develop the latest advanced tools in molecular biology research and molecular diagnostics.

    GenomeWeb’s editorial mission is to serve readers with exclusive, in-depth coverage of the technology, institutions, and scientists that make up the worldwide research enterprise of molecular biology. We operate the largest online news organization focused on advanced research tools in genomics, proteomics, and bioinformatics.

    GenomeWeb readers can be found in major biopharmaceutical companies, top research universities, biomedical institutes, and government laboratories.


    ASD MEDIA

    Supporters
    http://www.asd-network.com

    Professionals in the Aerospace & Defence market use the ASD Media internet platforms to:
    • Be informed on the latest market developments; www.asd-network.com
    • Find the latest business news; www.asd-network.com
    • Find the upcoming events; www.asd-network.com
    • Find companies and organizations; www.asdsource.com
    • Distribute news globally. www.asdwire.com
    The ASD Media platforms are well known and used intensively, your company is able to benefit from these large numbers of users. Be informed with ASD-Network; Create exposure for your company with ASDSource, distribute your news with ASDWire or advertise with us, build your brand and increase traffic to your company’s website.

    For more detailed information please contact with: ASD MEDIA
    Stefan.koopman@asdmedia.nl


    pharmaphorum

    Supporters
    http://www.pharmaphorum.com

    pharmaphorum drives innovation within the pharmaceutical industry, by bringing healthcare together through a suite of media services that help produce and disseminate thought leadership, combined with an online platform for communicating messages to a global audience.Visit www.pharmaphorum.com


    American Pharmaceutical Review

    Supporters
    http://www.americanpharmaceuticalreview.com

    Start receiving your free copy today. American Pharmaceutical Review is a review of the drug pipeline from the late discovery phase through manufacturing. American Pharmaceutical Review prides itself on having the most relevant, unbiased and informative editorial in the industry. You will find that all of our editorial is highly technical and written by government agencies, consultants, academics, and large pharmaceuticals companies. American Pharmaceutical Review covers several key topics that are important to drug production:Separations and purification, Drug Delivery, Biopharmaceutical Processing, Biopharmaceutical Development, Formulation development, Manufacturing, Microbiology, Instrumentation, Spectroscopy


    Drug Discovery Today

    Supporters
    http://www.drugdiscoverytoday.com/

    Drug Discovery Today covers the whole of the preclinical drug discovery process. The reviews are cutting edge, written by experts in their respective fields and cover all aspects of drug discovery from genomic and proteomic approaches, computational drug design, medicinal chemistry and the translation of these sciences to therapies.


    Labiotech.eu

    Supporters
    https://goo.gl/DRE2Gp

    Labiotech.eu is the leading digital media covering the European Biotech industry. Over 100,000 monthly visitors use it to keep an eye on the business and innovations in biotechnology. Hope you'll enjoy reading our stories!


    Pharmacircle

    Supporters
    http://www.pharmacircle.com

    PharmaCircle is an innovative knowledge management company serving the current and future global leaders in the Pharmaceutical and Biotechnology related industries. PharmaCircle is a one stop information and analysis source for pipeline, products, clinical trials, drug delivery technologies, deals and acquisitions, company financials, venture capital investments, product sales, pharmaceutical services, news, patents and more….


    IPI

    Supporters
    http://international-pharma.com/

    International Pharmaceutical Industry is a peer-reviewed journal. We are committed to editorial integrity. Supported by an elite group of reviewers and industry experts, IPI brings you contemporary and authoritative articles which will guide the industry in the best practice in regulatory issues, market analysis, drug discovery, development, delivery methods, clinical research, laboratories, analytical testing, custom and contract manufacturing, primary and secondary packaging, logistics and supply chain management.


    Drug Development Technology

    Supporters
    http://www.drugdevelopment-technology.com

    Drugdevelopment-technology.com covers every aspect of the drug development and research process, from conception to pre-FDA approval. Our global network of journalists updates the site with the latest and most significant industry developments. This coverage allows us to provide everyone - from senior management through to research and QA staff – with in-depth reviews of the latest projects, advance notice of new product releases and analysis of the latest procedural and legislative developments.


    Pharma Journalist

    Supporters
    http://www.pharmajournalist.com

    Pharma Journalist is a product of Kellen Media. Pharma Journalist is one of the leading website covering the need of global Pharmaceutical Industry. Articles like latest news, trends, analysis, market report, press releases, whitepapers, case studies, etc. published on pharmajournalist.com helps Industry professionals and decision makers to stay on the top of this fast-paced industry. Pharma Journalist aims of providing fast and informative articles to its readers and subscribers.


    Gate2Biotech

    Supporters
    http://www.gate2biotech.com

    Gate2Biotech is a portal that unites biotechnological community in Central Europe. It covers all the news in the field of biotechnology. Thanks to the the portal the companies engaged in the field can easily search for research institutions and other partners to solve technical problems they are facing and here they can also present their services offer to potential partners from the Czech Republic and abroad. Gate2Biotech portal serves as a bridge connecting scientific and commercial sector. It incorporates offices and support organizations dedicated to promoting transfer of innovative technologies into a unified communication platform of Czech and international biotechnologies. As a mediator of information it draws attention to biotechnologies and support of their application and transfer into practice. It also functions as a tool for encouraging non-professionals (especially scientists and students) towards innovative business or applied research.


    Pharmiweb

    Supporters
    http://www.pharmiweb.com

    Established in October 2003, PharmiWeb Solutions is an energetic, innovative provider of web-based solutions for the pharmaceutical sector, with customers such as AstraZeneca, Roche, Servier Laboratories, and Merck With solutions in three key areas: Online Publishing, e-Business and Mobile Computing, we deliver connectivity – between people and applications – unlocking islands of data and knowledge. We own some of the sector’s most innovative Online Publications: PharmiWeb.com, HospitalPharma.com and Detail-Direct.com. We are actively developing solutions for Mobile Computing platforms. For example, our PharmiTabTM e-pharmacy solution runs real-time patient data and prescribing transactions in a busy hospital environment, on a TabletPC, wireless client/server platform. e-Business solutions range from e-Detailing, to Online Market Research, all designed to increase reach, increase sales, and to reduce administration and costs.


    Pharmalicensing

    Supporters
    http://www.pharmalicensing.com

    Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide. Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of Cognis Group, Inc.


    Gene Therapy Net

    Supporters
    http://www.genetherapynet.com

    Gene Therapy Net is the information resource for basic and clinical research in gene therapy, and the site serves as a network in the exchange of gene therapy information and breaking news items. Visitors can keep track of the latest scientific papers, conference announcements, gene therapy jobs, regulations and guidelines


    On Drug Delivery

    Supporters
    http://www.ondrugdelivery.com/subscribe

    ONdrugDelivery provides 30,000 readers throughout global pharma/biopharma, with the latest, most pertinent industry information and intelligence about the drug delivery-related ideas, technologies, services and products the sector is developing. Established in 2004, and trusted throughout the industry for its high quality contributions from leading drug delivery experts, ONdrugDelivery is a must for pharma / biotech industry professionals who need to know what’s going on in drug delivery. Subscribe online today to the print or free digital edition: www.ondrugdelivery.com/subscribe.


    Pharmaceutical Technology

    Supporters
    http://www.pharmaceutical-technology.com

    Pharmaceutical-technology.com is the only website focusing specifically on issues relevant to pharmaceutical professionals working with technology, be it development, engineering, IT or production. Pharmaceutical-technology.com brings you the latest in industry projects and updates, along with the news, views and trends that leading professionals – from senior executives to manufacturing managers and heads of procurement – require to stay on top of their field.


    Mednous

    Supporters
    http://www.MedNous.com

    MedNous is a print publication and website about medical innovation in Europe. It carries exclusive interviews with companies that are at the forefront of medical technology, as well as contributor articles from prominent practitioners. Our mission is to identify significant advances in medicine and to explain how this innovation is being commercialised. In doing so, we talk to venture capitalists about what products and platforms they are supporting. We report on how regulators cope with the accelerating pace of innovation. And we regularly cover the latest developments in the discovery and development of new medical concepts in the area of antibodies, vaccines, small molecules, regenerative medicine and nanomedicines. MedNous combines the English word for medicine with the Greek word for intellect. And those with nous are readers of our publication. Visit our website: www.mednous.com

    Online Virtual Event

    Online Virtual Event
    United Kingdom

    Online Virtual Event

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.